2H0 Stock Overview Does not have significant operations. More details
Risk Analysis See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Exicure, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Exicure Historical stock prices Current Share Price US$1.48 52 Week High US$4.23 52 Week Low US$1.30 Beta 1.28 1 Month Change 0% 3 Month Change -17.32% 1 Year Change -29.19% 3 Year Change -97.88% 5 Year Change -99.61% Change since IPO -99.60%
Recent News & Updates
Exicure, Inc. Announces Board Changes Nov 28
Exicure Request for Subsequent Extension to Nasdaq Hearings Panel Till December 17 Nov 15
Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024 Sep 19
Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) Sep 14
Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules Aug 27
High number of new and inexperienced directors Aug 15 See more updates
Exicure, Inc. Announces Board Changes Nov 28
Exicure Request for Subsequent Extension to Nasdaq Hearings Panel Till December 17 Nov 15
Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024 Sep 19
Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) Sep 14
Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules Aug 27
High number of new and inexperienced directors Aug 15
Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics Aug 09
Exicure Receives Positive Listing Determination from Nasdaq Aug 02
Exicure Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1) Jun 26
Exicure, Inc., Annual General Meeting, Jun 28, 2024 Jun 13
Exicure, Inc. Receives Nasdaq Notice of A Delisting Determination May 24 Exicure, Inc. announced delayed 10-Q filing May 17
Exicure, Inc. announced delayed annual 10-K filing Apr 02
New minor risk - Financial data availability Feb 27
No independent directors Feb 14
Exicure Receives Non-Compliance Notice From Nasdaq Jan 17
Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q Nov 29
Exicure, Inc. announced delayed 10-Q filing Nov 15
Exicure, Inc. Appoints Minhee Eom to the Board Sep 28
Exicure Receives Non-Compliance Notice From Nasdaq Sep 14 Exicure, Inc. Announces Executive Changes
Less than half of directors are independent Aug 15
Exicure Notifies Nasdaq Regarding Continued to be Not in Compliance with Rule 5605(c)(2)(A) Aug 06
Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q May 22
CBI USA Inc Sends a Letter to Exicure Inc May 18
Exicure, Inc. announced delayed 10-Q filing May 16
No independent directors Apr 13
Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee Feb 12
Exicure Receives Notice from Nasdaq Regarding No Longer in Compliance with Nasdaq's Independent Director and Audit Committee Requirements Jan 23
Exicure, Inc. Announces Resignation of Jiyoung Hwang from the Board of Directors Jan 22
Exicure, Inc. Announces Executive Changes Jan 01 Exicure, Inc. Contemplates Bankruptcy Nov 15
Exicure, Inc. announced that it expects to receive $5.44 million in funding from CBI Inc. Sep 28
Exicure Receives Noncompliance Notice from Nasdaq Aug 25
Second quarter 2022 earnings released Aug 17
Exicure Regains Compliance with Nasdaq Minimum Bid Price Requirement Jul 21
Exicure Announces Receipt of Nasdaq Notice of Non-Compliance Jun 30
First quarter 2022 earnings released: US$0.069 loss per share (vs US$0.14 loss in 1Q 2021) May 18 Exicure, Inc. announced that it expects to receive $5.040289 million in funding from CBI USA, Inc, Abingworth LLP May 12
High number of new and inexperienced directors Apr 27
Exicure, Inc., Annual General Meeting, May 27, 2022 Apr 13 Exicure, Inc. Announces Executive, Board and Committee Changes
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Exicure, Inc. Investors Jan 12
Exicure Receives A Letter from the Staff Nasdaq Stock Market Jan 07
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Exicure, Inc Dec 15
Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020) Aug 18 Exicure, Inc.(NasdaqCM:XCUR) dropped from Russell Microcap Value Index
Exicure, Inc. Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients with Unmet Medical Needs May 14
First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020) May 14
Co-Founder & Director Chad Mirkin has left the company May 01
Exicure, Inc. Announces Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients with Glioblastoma Mar 12
Full year 2020 earnings released: US$0.28 loss per share (vs US$0.46 loss in FY 2019) Mar 12
Revenue misses expectations Mar 12
Exicure, Inc. Announces David R. Walt Did Not Stand for Re Election Mar 11
Exicure Announces Appointments of Board of Directors Mar 10
New 90-day high: €2.06 Feb 11
Exicure Appoints James Sulat to Board of Directors Jan 19
Exicure, Inc. Announces That the U.S. Food and Drug Administration (Fda) Has Granted Fast Track Designations for Its Clinical Product Candidate Jan 12
New 90-day high: €1.66 Jan 07
Exicure, Inc. Announces Executive Changes Jan 06
New 90-day low: €1.22 Nov 19
Third quarter 2020 earnings released: US$0.10 loss per share Nov 13
Revenue beats expectations Nov 13
Exicure, Inc. Announces Resignation of Helen S. Kim as A Class II Director Nov 13
Exicure Presents Updates Phase 1b Data from the Ongoing Phase 1B/2 Clinical Trial Evaluating Intratumoral Cavrotolimod Nov 10
New 90-day low: €1.24 Nov 02
New 90-day low: €1.39 Oct 06
Exicure, Inc. Announces Executive Changes, Effective September 30, 2020 Sep 19
New 90-day low - €1.55 Sep 15
New 90-day low - €1.70 Aug 26
Earnings released Aug 12 Shareholder Returns 2H0 DE Biotechs DE Market 7D 0% 1.2% 2.3% 1Y -29.2% -5.6% 16.7%
See full shareholder returns
Return vs Market: 2H0 underperformed the German Market which returned 7.7% over the past year.
Price Volatility Is 2H0's price volatile compared to industry and market? 2H0 volatility 2H0 Average Weekly Movement n/a Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 2H0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 2H0's volatility change over the past year.
About the Company Exicure, Inc. does not have significant operations. previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Show more Exicure, Inc. Fundamentals Summary How do Exicure's earnings and revenue compare to its market cap? 2H0 fundamental statistics Market cap €32.35m Earnings (TTM ) -€3.85m Revenue (TTM ) €480.15k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2H0 income statement (TTM ) Revenue US$500.00k Cost of Revenue US$0 Gross Profit US$500.00k Other Expenses US$4.51m Earnings -US$4.01m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.19 Gross Margin 100.00% Net Profit Margin -801.40% Debt/Equity Ratio 0%
How did 2H0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/11/24 17:03 End of Day Share Price 2024/08/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Exicure, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null BMO Capital Markets Equity Research Keay Nakae Chardan Capital Markets, LLC Yatin Suneja Guggenheim Securities, LLC
Show 2 more analysts 
